SEARCH
Magellan
Improving outcomes from discovery to diagnostics Magellan

Governance

Executive management team

Robert J. Rosenthal, PhD – President and Chief Executive Officer

Michael Mullen – Chief Financial Officer

Darren Braccia – Vice President of Business Development

Steven E. Diamond, PhD – Chief Scientific Officer

Philip Ayers – Corporate Counsel

Adrian Bunce – President, Dynex Technologies

Mike Burke – President, TREK Diagnostic Systems

Board of directors

Herbert Hooper, PhD – Magellan Biosciences Chairman; Ampersand Ventures Managing General Partner (private equity investments)

Stuart A. Auerbach – Ampersand Ventures General Partner (private equity investments)

Michael F. Bigham – Abingworth Management Director, responsible for the Boston office

Heiner Dreismann, PhD – Former President and CEO, Roche Molecular Diagnostics (PCR-based (polymerase chain reaction) molecular diagnostic tests)

Laurence R. McCarthy, PhD – Former President and CEO of Focus Diagnostics, Inc., (developer of novel assays and diagnostic-testing services)

Daniel R. Omstead, Eng.ScD – President and CEO, Hambrecht & Quist Capital Management

Robert J. Rosenthal, PhD – Magellan Biosciences President and CEO

Michael E. Woehler, PhD – President and CEO, Medifacts International (contract clinical-trial services to the pharmaceutical, biotech, and medical-device industries)

Site map Terms and Conditions of Use Privacy Policy ©2005-2008. Magellan Biosciences, Inc. All rights reserved. CONTACT US HOME